Gilbert Glady
European Bio Immune(G)ene Medicine Association, France
Keynote: J Infec Dis Treat
In recent years, many discoveries have profoundly changed our knowledge on the relationships between bacteria and our cells, whether they are immuno-competent cells or other somatic cells that are subject to bacterial attack. We now better know how our cells detect bacterial aggressors using receptors of restricted specificity belonging to innate immunity and able to identify specific molecular patterns located on bacterial membranes, being Gram-positive or negative germs or mycobacteria. Once this identification has been carried out, a whole arsenal of inflammatory reactions is triggered in order to destroy as quickly as possible bacterial germs in their aggression phase. Faced with these defensive strategies deployed by the innate immune system, bacteria do not remain inactive and in turn implement a set of molecular reactions, including the mighty system of injectisomes, to elude the immune responses aiming at their neutralization or even their final destruction. What if, for a therapeutic purpose, we could counteract the strategies implemented by bacteria to beat them at their own game? This is what the Bio Immune(G)ene Medicine-in short BI(G)MED- is attempting to do quite successfully by using ultra-low doses of molecules and relying on the general principle of Hormesis. A short description of the method and some clinical examples will help to better understand the merits of this sub-lingual nanotherapy, which is moreover devoid of any undesirable side effects.
Gilbert Glady has graduate from Med School in 1977 and has completed his MD at the age of 27 years from Strasbourg University of medicine and postdoctoral studies from Besancon and Paris-Nord universities of medicine and was then an Intern in Onco-Hematology in the university clinic for several years. After a specialization in homeopathy and naturopathy in Paris, he returned to the Alsace region to work as a Private Practitioner. Through his work and encounters, he developed interest and expertise in Immunology and Immunogenetics that leaded him to nanomedicine and nanobiotechnology. He thus became in 2010, the Creator of the BI(G)MED method (Bio Immune (G)ene Medicine) and Director of EBMA, the European association responsible for communication and trainings in the field of BI(G) MED. He has participated in numerous international congresses in immuno-allergology, infectiology and oncology with posters and oral presentations and is the Author of several publications on nanobiotherapy in different journals.
E-mail: info@ebma-europe.com
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 